Centers For Medicare & Medicaid Services Issues ICD-10-PCS Codes For Humacyte's Human Acellular Vessel
Portfolio Pulse from Benzinga Newsdesk
Humacyte, Inc. (NASDAQ:HUMA) announced the issuance of four new ICD-10-PCS codes by the Centers for Medicare & Medicaid Services for procedures using its Human Acellular Vessels (HAVs). These codes will be effective from October 1, 2024. Additionally, the FDA has given the HAV a common name: 'acellular tissue engineered vessel' (ATEV).
June 17, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Humacyte, Inc. received four new ICD-10-PCS codes for its Human Acellular Vessels (HAVs), effective October 1, 2024. The FDA has also named the HAV 'acellular tissue engineered vessel' (ATEV).
The issuance of new ICD-10-PCS codes and the FDA's naming of the HAV are significant regulatory milestones for Humacyte. These developments are likely to positively impact the company's stock price in the short term as they pave the way for broader adoption and recognition of its products.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100